1117. Deputy Ken O'Flynn asked the Minister for Health whether a final, formally approved workforce model has been signed off for Heather House Community Nursing Unit; if so, the date of approval; and if not, the reason a unit is reopening in advance of such approval. [32744/26]
1118. Deputy Ken O'Flynn asked the Minister for Health to confirm whether the current staffing levels at the dementia-specific unit at Heather House Community Nursing Unit are fully compliant with HIQA standards for residential care settings; and whether any risks or variances have been identified. [32745/26]
1119. Deputy Ken O'Flynn asked the Minister for Health whether full funding has been formally approved and allocated for the complete staffing complement required to operate the dementia-specific unit at Heather House Community Nursing Unit at full capacity; and if not, the shortfall. [32746/26]
1120. Deputy Ken O'Flynn asked the Minister for Health whether the staffing model originally developed for a 104-bed facility has been revised to reflect the reduction in capacity to approximately 102 beds and the dementia unit reduction from 19 to 17 beds; and to provide the updated model. [32747/26]
1121. Deputy Ken O'Flynn asked the Minister for Health whether any patients in the State currently have access to omaveloxolone, marketed as Skyclarys, for Friedreich’s ataxia through compassionate use, named patient access, hospital-level approval, exceptional funding, or any other interim access mechanism pending a final HSE reimbursement decision; and if she will make a statement on the matter. [32771/26]
1122. Deputy Ken O'Flynn asked the Minister for Health the number of patients in the State known to the HSE or the Department of Health who are clinically eligible for treatment with omaveloxolone, marketed as Skyclarys, for Friedreich’s ataxia; and if this number has informed any budget impact assessment. [32772/26]
1123. Deputy Ken O'Flynn asked the Minister for Health whether the HSE has a target timeline for completing reimbursement decisions in respect of orphan medicines or medicines for progressive rare diseases; and if no such target exists, whether one is under consideration. [32773/26]
1124. Deputy Ken O'Flynn asked the Minister for Health whether the HSE has any escalation process where a reimbursement application concerns a progressive neurological condition in which delay may lead to irreversible deterioration. [32774/26]
1125. Deputy Ken O'Flynn asked the Minister for Health whether the HSE has considered international reimbursement or access decisions in respect of omaveloxolone, marketed as Skyclarys, including decisions in France, Italy, Germany or other comparable European countries, as part of the Irish reimbursement process. [32775/26]
1126. Deputy Ken O'Flynn asked the Minister for Health whether the Department or HSE has examined the favourable reimbursement opinion issued in France for Skyclarys in Friedreich’s ataxia, and whether such international assessments are considered in Irish rare disease reimbursement decisions. [32776/26]
1127. Deputy Ken O'Flynn asked the Minister for Health whether the Department or HSE is aware that Italy’s medicines authority approved reimbursement of Skyclarys for Friedreich’s ataxia in December 2025, and whether this decision has been considered in the Irish process. [32777/26]
1128. Deputy Ken O'Flynn asked the Minister for Health whether the HSE has received a commercial proposal from Biogen Idec Ireland Limited in respect of omaveloxolone, marketed as Skyclarys, since 16 April 2026; and if not, what steps the HSE is taking to progress the matter. [32778/26]
1129. Deputy Ken O'Flynn asked the Minister for Health whether any statutory, contractual, policy or administrative time limits apply where a marketing authorisation holder has been invited to submit a commercial proposal for a medicine but has not yet done so. [32779/26]
1130. Deputy Ken O'Flynn asked the Minister for Health whether she will consider introducing a formal interim access pathway for rare disease medicines where a treatment has European marketing authorisation, there is no alternative disease-modifying therapy available, and the reimbursement process remains unresolved. [32780/26]
1149. Deputy Ken O'Flynn asked the Minister for Health whether the review of insourcing published on 1 July 2025 included any quantified modelling of the impact of cessation on waiting list volumes and waiting times; and if so, to provide the outputs of that modelling. [32884/26]
1150. Deputy Ken O'Flynn asked the Minister for Health to specify the total volume of procedures, outpatient appointments, and diagnostic interventions delivered through third-party insourcing in each of the years 2023, 2024 and 2025, and the proportion this represented of total activity. [32885/26]
1151. Deputy Ken O'Flynn asked the Minister for Health to outline the clinical specialties and procedures in which third-party insourcing was utilised prior to its reduction; and whether equivalent in-house capacity now exists in each category. [32886/26]
1152. Deputy Ken O'Flynn asked the Minister for Health the number of additional theatre sessions, outpatient clinics, and diagnostic capacity units that have been added within the public system in 2025 and 2026 to replace insourcing activity. [32887/26]
1153. Deputy Ken O'Flynn asked the Minister for Health whether any risk assessment was conducted regarding potential increases in waiting times or patient deterioration following the cessation of insourcing; and if so, to provide details. [32888/26]
1154. Deputy Ken O'Flynn asked the Minister for Health whether any patients previously scheduled for treatment under insourcing arrangements have experienced delays or rescheduling as a result of the policy change; and if so, the number affected. [32889/26]
1155. Deputy Ken O'Flynn asked the Minister for Health to provide a comparative cost per procedure between third-party insourcing, outsourcing via the National Treatment Purchase Fund, and direct in-house provision for the most common procedures. [32890/26]
1156. Deputy Ken O'Flynn asked the Minister for Health whether any clinical governance incidents, adverse outcomes, or audit findings relating to third-party insourcing informed the decision to cease its use; and if so, to provide details. [32891/26]
1157. Deputy Ken O'Flynn asked the Minister for Health whether her Department receives aggregated national reporting on waiting times for access to PrEP services; and if so, to provide the most recent data. [32892/26]
1158. Deputy Ken O'Flynn asked the Minister for Health whether a national register or centralised data system exists to track demand for PrEP services across all providers; and if not, whether one is planned. [32893/26]
1159. Deputy Ken O'Flynn asked the Minister for Health the total number of clinics currently delivering PrEP services nationally, including both public and private providers, and whether this number has increased since 2023. [32894/26]